Laurent Audoly

USPTO Granted Patents = 11 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Toulouse, FR (2020)
Mahwah, NJ (US) (2017 - 2022)

Company Filing History:

10 out of 36

Pieris Pharmaceuticals Gmbh

Pieris Pharmaceutical Gmbh

patent

where one patent can have more than one assignee

Years Active: 2017-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11382951 - Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors (2022-07-12),

2. 11034738 - Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2) (2021-06-15),

3. 10857202 - Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors (2020-12-08),

4. 10526384 - Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof (2020-01-07),

5. 10526382 - Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof (2020-01-07),

6. 10398754 - Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors (2019-09-03),

7. 10064963 - Methods and compositions for treating disorders (2018-09-04),

8. 10016483 - Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors (2018-07-10),

9. 9950034 - Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation (2018-04-24),

10. 9610356 - Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation (2017-04-04),

11. 9572863 - Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors (2017-02-21),

Title: Inventor Spotlight: Laurent Audoly

Introduction

Laurent Audoly is an innovative inventor based in Mahwah, NJ, USA, who has made significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, his work primarily focuses on groundbreaking methods for treating various disorders through advanced pharmaceutical compositions.

Latest Patents

Among his latest patents, Audoly has developed methodologies aimed at preventing or treating disorders by inhibiting the binding of interleukin-4 (IL-4) and interleukin-13 (IL-13) to their respective receptors. This innovative work is crucial for addressing conditions associated with an increase in the Th2 immune response, such as allergic asthma, rhinitis, and chronic obstructive pulmonary disease. Moreover, he has patented nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) that bind angiopoietin-2 (Ang-2). These formulations hold potential in pharmaceutical applications, including the capacity to inhibit or reduce angiogenesis.

Career Highlights

Audoly has had a distinguished career, having worked with reputable companies like Pieris Pharmaceuticals and AstraZeneca. His extensive experience in these organizations has significantly influenced his innovative approaches and contributed to his success as a patent holder.

Collaborations

Throughout his career, Laurent Audoly has collaborated with prominent figures in the industry, including colleagues such as Andreas Hohlbaum and Hendrik Gille. These partnerships reflect his commitment to advancing the field through shared expertise and collaborative research.

Conclusion

With a robust portfolio of patents and a wealth of experience in the pharmaceutical industry, Laurent Audoly exemplifies the innovative spirit of modern inventors. His dedication to improving health outcomes through his inventions continues to inspire and advance the field of medical treatment.

This text is generated by artificial intelligence and may not be accurate.